of drug-resistant tuberculosis. The United States Government continues to be a lead funder of global tuberculosis research and development, contributing 40 percent of the total $772,000,000 in global funding in 2017, and can catalyze more investments from other countries. (7) The rate of new cases of tuberculosis in countries that receive United States bilateral assistance for tuberculosis prevention, treatment, and control has fallen by one quarter since 2000 demonstrating the effectiveness of United States programs and activities. (8) In September 2018, United Nations Member States in the first United National High Level Meeting on Tuberculosis committed to ending the epidemic in all countries, and pledge[d] to provide leadership and to work together to accelerate our national and global collective actions, investments, and innovations urgently to fight this preventable and treatable disease, as reflected in United Nations General Assembly Resolution A/RES/73/3. (9) On September 26, 2018, the United Nations convened the first High Level Meeting on Tuberculosis, where 120 countries signed a Political Declaration to accelerate progress against tuberculosis, including commitments to increase funding for tuberculosis control and research and development programs, as well as ambitious goals to successfully treat 40,000,000 people with tuberculosis and prevent at least 30,000,000 from becoming ill between 2018 and 2022. (10) On September 26, 2018, the Administrator for the United States Agency for International Development (USAID) announced a new business model to support the fight to end tuberculosis (TB). Through $30,000,000 in funding and a new performance-based Global Accelerator to End TB, USAID will catalyze investments to meet the target set by the United Nations High-Level Meeting on tuberculosis of treating 40,000,000 people with the disease by 2022. The Accelerator will increase support to governments and local partners as part of a multisectoral approach to ending tuberculosis. (11) It is essential that